1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Xifaxan (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Xifaxan (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Summary

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Xifaxan (rifaximin) was developed by Alfa Wassermann, and is currently approved for the treatment of hepatic encephalopathy and traveler's diarrhea in the US and 5EU, except in France. In 1996, Salix Pharmaceuticals gained the exclusive rights to Xifaxan in the US, and is currently developing this product for the treatment of patients with IBS-D (Salix Pharmaceuticals, 2014).

Scope

- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Xifaxan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Xifaxan for the top 7 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Xifaxan performance.
- Obtain sales forecast for Xifaxan from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, the UK, and Japan).

Table Of Contents

Xifaxan (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.2 Classification 12
3.3 Symptoms 13
3.4 Prognosis 14
3.5 Quality of Life 14
4 Disease Management 15
4.1 Diagnosis and Treatment Overview 15
4.1.1 Diagnosis 15
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 17
4.1.3 Clinical Practice 20
5 Competitive Assessment 22
5.1 Overview 22
6 Unmet Need and Opportunity 24
6.1 Overview 24
6.2 More Effective Pharmacotherapies 25
6.2.1 Unmet Need 25
6.2.2 Gap Analysis 26
6.2.3 Opportunity 27
6.3 Therapies for the IBS-D Subtype 27
6.3.1 Unmet Need 27
6.3.2 Gap Analysis 28
6.3.3 Opportunity 28
6.4 Therapies for the IBS-M Subtype 28
6.4.1 Unmet Need 28
6.4.2 Gap Analysis 29
6.4.3 Opportunity 29
6.5 Therapies to Address Abdominal Pain and Bloating Symptoms 29
6.5.1 Unmet Need 29
6.5.2 Gap Analysis 30
6.5.3 Opportunity 30
6.6 Improved Diagnosis Rate for IBS 31
6.6.1 Unmet Need 31
6.6.2 Gap Analysis 31
6.6.3 Opportunity 31
7 Pipeline Assessment 33
7.1 Overview 33
7.2 Promising Drugs in Clinical Development 33
8 Xifaxan (rifaximin) 36
8.1 Overview 36
8.2 Efficacy 38
8.3 Safety 40
8.4 Dosing and Formulation 41
8.5 Potential Clinical and Commercial Positioning 42
8.6 SWOT Analysis 43
8.7 Forecast 43
9 Appendix 45
9.1 Bibliography 45
9.2 Abbreviations 48
9.3 Methodology 50
9.4 Forecasting Methodology 50
9.4.1 Diagnosed IBS Patients 50
9.4.2 General Pricing Assumptions 51
9.4.3 Generic Erosion 52
9.4.4 Pricing of Pipeline Agents 52
9.5 Primary Research - KOLs Interviewed for This Report 53
9.6 Primary Research - Prescriber Survey 55
9.7 About the Authors 56
9.7.1 Analyst 56
9.7.2 Therapy Area Director 56
9.7.3 Global Head of Healthcare 57
9.8 About GlobalData 58
9.9 Disclaimer 58

1.1 List of Tables

Table 1: Common Symptoms of IBS 13
Table 2: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS 16
Table 3: Treatment Guidelines for IBS 18
Table 4: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014† 19
Table 5: Leading Branded Treatments for IBS, 2014 23
Table 6: Unmet Needs and Opportunities in IBS 25
Table 7: Drugs in Late-Stage Clinical Development for IBS, 2014 35
Table 8: Product Profile - Xifaxan 38
Table 9: Safety of Xifaxan - Most Frequently Reported Adverse Events 41
Table 10: Xifaxan SWOT Analysis, 2014 43
Table 11: Global IBS Sales Forecasts ($m) for Xifaxan, 2013-2023 44
Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 55

1.2 List of Figures

Figure 1: Summary of Pharmacotherapies Used to Treat IBS 21
Figure 2: IBS - Phase IIb-III Pipeline, October 2014 34
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023 34
Figure 4: Clinical and Commercial Positioning of Xifaxan 42

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Gastroesophageal Reflux Disease (GERD)  - Market Insights, Epidemiology and Market Forecast-2023

Gastroesophageal Reflux Disease (GERD)  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Gastroesophageal Reflux Disease (GERD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Gastroesophageal ...

Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023

Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Anti Peptic Ulcer Drugs Markets in China

Anti Peptic Ulcer Drugs Markets in China

  • $ 4000
  • Industry report
  • January 2017
  • by Asia Market Information & Development Company

China’s demand for Anti Peptic Ulcer Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...


Download Unlimited Documents from Trusted Public Sources

Gastrointestinal Drug Industry in the US - Forecast

  • January 2017
    4 pages
  • Gastrointestina...  

    Digestive Syste...  

    Hormone  

  • United States  

View report >

Gastrointestinal Drug Industry in the US

  • January 2017
    8 pages
  • Gastrointestina...  

    Digestive Syste...  

  • United States  

View report >

Gastrointestinal Drug Markets in the US

  • January 2017
    11 pages
  • Gastrointestina...  

    Digestive Syste...  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.